https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K213944
Moderna Seeks FDA Emergency Use Nod For COVID-19 Shot In Kids 2-6 Years
Moderna Inc (NASDAQ: MRNA)
Related Posts
PaySign Q1 EPS $(0.01) Up From $(0.03) YoY, Sales $8.22M Beat $8.22M Estimate
PaySign (NASDAQ:PAYS) reported quarterly losses of $(0.01) per share. This is a 66.67 percent increase over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $8.22
Rubius Therapeutics To Present Trials In Progress Poster For The Phase 1/2 Clinical Trial Of Rtx-224 In Select Advanced Solid Tumors At The 2022 American Society Of Clinical Oncology Annual Meeting
Rubius Therapeutics to Present Trials in Progress Poster for the Phase 1/2 Clinical Trial of RTX-224 in Select Advanced Solid Tumors at the 2022 American Society of Clinical Oncology Annual Meeting
CAMBRIDGE, Mass., May
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
Here's a roundup of top developments in the biotech space over the last 24 hours.